Marshall Edwards -- MSHL | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Marshall Edwards -- MSHL

An SI Board Since January 2005

Posts	SubjectMarks	Bans	Symbol
26	7	0	MSHL

Emcee: tuck	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
26	DRUG DEVELOPMENT \| October 05, 2007 Making Chemo Irresistible A virtual biopha	sim1	-	10/7/2007
25	>>OVArian TUmor REsponse ('OVATURE') Trial Enrolls First U.S. Pati	tuck	-	6/1/2007
24	MSHL doesn't have to pay Novogen an $8 million milestone this December, rath	tuck	-	6/13/2006
23	>>WASHINGTON and SYDNEY, Australia, May 16 /PRNewswire/ -- Biotechnology c	tuck	-	5/16/2006
22	MSHL exercises its option to inlicense the Novogen drugs: >>WASHINGTON an	tuck	-	5/15/2006
21	>>Yale Researchers Find Phenoxodiol Restores Sensitivity to Chemotherapy i	tuck	-	3/30/2006
20	Red Flag here? Inhibition of AKT may promote metastasis (thanks to Johm McCarthy	tuck	-	11/22/2005
19	..<Kelly's statement that we should expect obvious progression in a 4 wee	kenhott	-	11/18/2005
18	One last note. As far as I can tell, "early stage" in this case means	tuck	-	11/17/2005
17	Actually, let me make a minor expansion on my last post. As a matter of semanti	tuck	-	11/17/2005
16	The market seems to be taking these results with a grain of salt. The cervical	tuck	-	11/17/2005
15	Researchers Report That Phenoxodiol Produces Anti-Cancer Responses in Women With	John McCarthy	-	11/17/2005
14	Phenoxodiol Delays Tumor Progression in Late-Stage Hormone Refractory Prostate C	John McCarthy	-	11/17/2005
13	[Final Results of a Phase Ib/IIa Study of Phenoxodiol in Hormone-Refractory Pros	tuck	-	11/15/2005
12	Interim results update: >>STAMFORD, Conn., Oct. 24 /PRNewswire-FirstCall/	tuck	-	10/24/2005
11	Thanks. Recommended reading: the 10-K: sec.gov Summarizes the clinical develo	tuck	-	9/16/2005
10	Don't remember. They weren't trading then, either. If I want something	scaram(o)uche	-	9/15/2005
9	>>The Company believes that it will have sufficient cash resources to fund	tuck	-	9/15/2005
8	Yeah, I'll second that. And thanks for the links, too.	scaram(o)uche	-	5/11/2005
7	Folks continue to follow this on the valuation thread . . . former pgs with	tuck	-	5/11/2005
6	Interim PIIb results look good, but the numbers look a little funny. See Messa	tuck	-	5/10/2005
5	Seems to be directly competitive to Telcyta, yes. Going after the same patient	tuck	-	4/16/2005
4	[Phenoxodiol Induces G1 Arrest by Specific Loss in CDK2 Activity by p53-Independ	tuck	-	4/16/2005
3	Tuck do you think this compound is a threat to telycta?The solo data did not loo	dogchow	-	3/26/2005
2	This amended S-1, pertaining to warrants, contains the most recent picture of th	tuck	-	1/12/2005

Go to reply# or date (mm/dd/yy):